Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.
The treatment is based on a novel targeting strategy for stopping autoimmunity in patients.
The innovation
The treatment is better way to treat systemic lupus erythematosus that shows markedly reduced autoimmunity without compromising B-cell survival.
Market need
Systemic lupus erythematosus is a debilitating and chronic autoimmune disease affecting more than five million people worldwide. Efficacy rates of current treatments are modest, and some deplete beneficial B-cells, greatly weakening the immune system and increasing risk of infections. On top of this, state-of-the-art treatments are costly.
Innovation status
Studies have identified a unique targeting approach based on selectively removing a highly inflammatory component of B-cell activating factor that is differential to the BAFF targeting approaches that are currently in the market or in development.
A biomarker to stratify patients for disease severity and the pathogenic mechanism has also been identified, enabling relevant subgroup targeting in clinical trials.
Contact
Anna Malinovitch
anna.malinovitch@unimelb.edu.au
Flyer
Download flyer for more information (PDF)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.